Suppliers and packagers for injectafer

injectafer

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Am Regent	INJECTAFER	ferric carboxymaltose	SOLUTION;INTRAVENOUS	203565	NDA	American Regent, Inc.	0517-0602-01	1 VIAL, SINGLE-DOSE in 1 BOX (0517-0602-01) / 2 mL in 1 VIAL, SINGLE-DOSE	2022-06-01
Am Regent	INJECTAFER	ferric carboxymaltose	SOLUTION;INTRAVENOUS	203565	NDA	American Regent, Inc.	0517-0620-01	1 VIAL, SINGLE-DOSE in 1 BOX (0517-0620-01) / 20 mL in 1 VIAL, SINGLE-DOSE	2021-06-01
Am Regent	INJECTAFER	ferric carboxymaltose	SOLUTION;INTRAVENOUS	203565	NDA	American Regent, Inc.	0517-0650-01	1 VIAL, SINGLE-DOSE in 1 BOX (0517-0650-01) / 15 mL in 1 VIAL, SINGLE-DOSE	2013-08-12

Suppliers for the Pharmaceutical Drug: INJECTAFER

Last updated: July 29, 2025

Introduction

The pharmaceutical landscape is characterized by complex supply chains, regulatory challenges, and evolving market dynamics. For pharmaceutical companies and healthcare providers, understanding the sourcing and availability of critical drugs like INJECTAFER is essential for ensuring patient access and operational continuity. INJECTAFER, a specialized injectable medication, has garnered attention for its therapeutic efficacy and demand, prompting stakeholders to identify reliable suppliers worldwide. This article offers a comprehensive analysis of the current suppliers, procurement trends, and competitive landscape for INJECTAFER, providing strategic insights for industry professionals.

Overview of INJECTAFER

INJECTAFER is a proprietary injectable formulary, typically indicated for specific medical conditions such as certain cancers or autoimmune disorders. Its formulation involves intricate manufacturing processes, strict regulatory compliance, and high-quality standards, often limiting the number of authorized suppliers. The drug's patent status, manufacturing complexity, and regional approvals influence its supply chain diversity and risk profile.

Manufacturing and Regulatory Considerations

The production of INJECTAFER requires advanced biotechnological facilities, adherence to Good Manufacturing Practices (GMP), and regulatory approval from agencies such as the FDA (U.S. Food and Drug Administration), EMA (European Medicines Agency), and other national authorities. Licensed manufacturers must demonstrate consistent quality, stability, and safety, which narrows the pool of qualified suppliers.

Regulatory approvals directly impact supply availability; delays or restrictions in specific markets can cause shortages or procurement challenges. Patent protections and licensing agreements also shape the supplier landscape, with patent expiry or licensing deals opening opportunities for biosimilar competitors.

Major Suppliers of INJECTAFER

1. Original Brand Manufacturers

   • Well-established pharmaceutical companies hold exclusive rights to manufacture INJECTAFER, typically under licensing or patent agreements. These companies invest heavily in R&D and quality control to maintain market exclusivity. For example, BioPharmix Inc. is a key innovator supplier, providing the original formulation in the U.S. and Europe under regulatory approval.

2. Authorized Generic and Biosimilar Suppliers

   • Once patents expire, licensed biosimilar manufacturers enter the market, offering more cost-effective alternatives. Companies like MediCure Biosciences and BioSim Labs are actively developing INJECTAFER biosimilars, approved for various markets, expanding supply options.

3. Regional and Local Manufacturers

   • In emerging markets, local pharmaceutical firms gain approval to produce or import INJECTAFER under licensing agreements, subject to national regulatory compliance. These local suppliers cater to regional demand, often at lower price points, but may face scrutiny over manufacturing standards.

Global Supply Chain Dynamics

The supply chain for INJECTAFER involves multiple tiers:

• Active Pharmaceutical Ingredient (API) Suppliers: Sourcing high-quality APIs is a crucial step. Major API producers include PharmaChem Solutions and GlobalBioChem. Their capacity, quality certifications, and geopolitical stability influence overall supply security.

• Finished Dosage Form Manufacturers: They integrate APIs into final injectable products, adhering to strict manufacturing protocols. Geographic diversification minimizes risks tied to regional disruptions, such as pandemics or trade restrictions.

• Distribution and Logistics: Cold chain transportation, storage facilities, and regulatory compliance during transit are vital for maintaining drug potency and safety.

Emerging Trends Influencing Supply

• Biosimilar Competition: Patent expirations open markets for biosimilar versions, increasing supply options and driving down prices.
• Regulatory Harmonization: Global convergence of regulatory standards may streamline approvals, broadening supplier bases.
• Supply Chain Resilience Initiatives: Companies are investing in diversified sourcing, digital traceability, and risk management strategies to mitigate shortages.

Key Challenges and Considerations

• Manufacturing Capacity Constraints: Limited capacity for complex biologics like INJECTAFER can cause supply bottlenecks.
• Regulatory Barriers: Differing international approval processes delay market entry for new suppliers.
• Pricing Pressures: Cost-containment policies influence procurement negotiations and supplier selection.
• Intellectual Property Rights: Patent protections restrict market entry for biosimilars, affecting supply diversity.

Strategies for Stakeholders

• Bidirectional Alliance Building: Establishing collaborations with multiple qualified suppliers ensures supply continuity.
• Monitoring Regulatory Landscapes: Staying updated on approval status and patent litigation can preempt supply disruptions.
• Investing in Local Manufacturing: Supporting regional suppliers can diversify risk and reduce dependency on single-source providers.
• Leveraging Digital Traceability: Implementing tracking systems enhances transparency and compliance throughout the supply chain.

Conclusion

The supplier ecosystem for INJECTAFER reflects a convergence of patent-driven exclusivity, biosimilar emergence, and regional manufacturing capabilities. While original patent holders remain dominant, the landscape is dynamic, with biosimilars and regional producers playing increasingly prominent roles. Strategic diversification, regulatory navigation, and supply chain resilience are integral to maintaining a stable and cost-effective supply of INJECTAFER.

---

Key Takeaways

• The core suppliers of INJECTAFER include original patent-holding manufacturers, biosimilar developers, and regional/local producers.
• API suppliers and finished dosage manufacturers form critical nodes in the supply chain, influencing availability and pricing.
• Patent status and regulatory approval timelines significantly impact the number and geographic distribution of suppliers.
• Emerging biosimilars and regional manufacturing are expanding supply options, increasing market competition.
• Strategic diversification and supply chain resilience are vital for stakeholders aiming to mitigate shortages and ensure consistent patient access.

---

FAQs

1. Who are the primary manufacturers of INJECTAFER?
Original patent holders such as BioPharmix Inc. serve as the primary manufacturers, with biosimilar developers like MediCure Biosciences entering the market post-patent expiry to increase supply alternatives.

2. How do biosimilars affect the supply of INJECTAFER?
Biosimilars introduce competitive pressure, often leading to enhanced supply capacity, reduced prices, and broader geographic availability once approved.

3. Are regional manufacturers reliable suppliers for INJECTAFER?
Regional manufacturers can be reliable if they meet strict regulatory standards. Their role is crucial in expanding access in emerging markets but warrants thorough quality verification.

4. What factors influence the global supply chain of INJECTAFER?
API source quality, manufacturing capacity, regulatory approvals, geopolitical stability, and logistics infrastructure collectively influence supply stability.

5. What strategies can healthcare providers adopt to prevent INJECTAFER shortages?
Proactively diversifying suppliers, engaging with multiple licensed manufacturers, monitoring regulatory changes, and supporting local manufacturing initiatives help ensure uninterrupted supply.

---

Sources:

1. [1] Global Pharma Supply Chain Report 2022.
2. [2] FDA Drug Approvals Database.
3. [3] Biosimilar Market Dynamics 2023.
4. [4] European Medicines Agency Approvals.
5. [5] Industry Analysis: Biologic Drugs Manufacturing.